By mid-2026, the industry has officially entered the era of "Proximal Complement Inhibition." This year, the focus is on the record-breaking success of Pegcetacoplan (Empaveli) and add-on therapies like Danicopan (Voydeya). These drugs target the C3 and Factor D proteins, specifically preventing the destruction of red blood cells in the spleen and liver—a complication known as...
English
Arabic
French
Spanish
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek